Table of Contents

1 Study Coverage

• 1.1 Antifungal Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Antifungal Drugs Market Size Growth Rate by Product
  • 1.4.2 Clotrimazole.
  • 1.4.3 Econazole.
  • 1.4.4 Miconazole.
  • 1.4.5 Terbinafine.
  • 1.4.6 Fluconazole.
  • 1.4.7 Ketoconazole.
  • 1.4.8 Amphotericin.
• 1.5 Market by End User
  • 1.5.1 Global Antifungal Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Antifungal Drugs Market Size
  • 2.1.1 Global Antifungal Drugs Revenue 2014-2025
  • 2.1.2 Global Antifungal Drugs Sales 2014-2025
• 2.2 Antifungal Drugs Growth Rate by Regions
  • 2.2.1 Global Antifungal Drugs Sales by Regions
  • 2.2.2 Global Antifungal Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Antifungal Drugs Sales by Manufacturers
  • 3.1.1 Antifungal Drugs Sales by Manufacturers
  • 3.1.2 Antifungal Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Antifungal Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Antifungal Drugs Revenue by Manufacturers
  • 3.2.1 Antifungal Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Antifungal Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Antifungal Drugs Price by Manufacturers
• 3.4 Antifungal Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Antifungal Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Antifungal Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Antifungal Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Antifungal Drugs Sales by Product
• 4.2 Global Antifungal Drugs Revenue by Product
• 4.3 Antifungal Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Antifungal Drugs Breakdown Data by End User

6 North America

• 6.1 North America Antifungal Drugs by Countries
  • 6.1.1 North America Antifungal Drugs Sales by Countries
  • 6.1.2 North America Antifungal Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Antifungal Drugs by Product
• 6.3 North America Antifungal Drugs by End User

7 Europe

• 7.1 Europe Antifungal Drugs by Countries
  • 7.1.1 Europe Antifungal Drugs Sales by Countries
  • 7.1.2 Europe Antifungal Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Antifungal Drugs by Product
• 7.3 Europe Antifungal Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Antifungal Drugs by Countries
  • 8.1.1 Asia Pacific Antifungal Drugs Sales by Countries
  • 8.1.2 Asia Pacific Antifungal Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Antifungal Drugs by Product
• 8.3 Asia Pacific Antifungal Drugs by End User

9 Central & South America

• 9.1 Central & South America Antifungal Drugs by Countries
  • 9.1.1 Central & South America Antifungal Drugs Sales by Countries
  • 9.1.2 Central & South America Antifungal Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Antifungal Drugs by Product
• 9.3 Central & South America Antifungal Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Antifungal Drugs by Countries
  • 10.1.1 Middle East and Africa Antifungal Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Antifungal Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Antifungal Drugs by Product
• 10.3 Middle East and Africa Antifungal Drugs by End User

11 Company Profiles

• 11.1 Asperqillus
  • 11.1.1 Asperqillus Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Asperqillus Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Asperqillus Antifungal Drugs Products Offered
  • 11.1.5 Asperqillus Recent Development
• 11.2 Alternaria
  • 11.2.1 Alternaria Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Alternaria Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Alternaria Antifungal Drugs Products Offered
  • 11.2.5 Alternaria Recent Development
• 11.3 Abbott Laboratories
  • 11.3.1 Abbott Laboratories Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Abbott Laboratories Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Abbott Laboratories Antifungal Drugs Products Offered
  • 11.3.5 Abbott Laboratories Recent Development
• 11.4 Pfizer
  • 11.4.1 Pfizer Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Pfizer Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Pfizer Antifungal Drugs Products Offered
  • 11.4.5 Pfizer Recent Development
• 11.5 GlaxoSmithKline
  • 11.5.1 GlaxoSmithKline Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 GlaxoSmithKline Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 GlaxoSmithKline Antifungal Drugs Products Offered
  • 11.5.5 GlaxoSmithKline Recent Development
• 11.6 Bayer Healthcare
  • 11.6.1 Bayer Healthcare Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Bayer Healthcare Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Bayer Healthcare Antifungal Drugs Products Offered
  • 11.6.5 Bayer Healthcare Recent Development
• 11.7 Novartis
  • 11.7.1 Novartis Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Novartis Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Novartis Antifungal Drugs Products Offered
  • 11.7.5 Novartis Recent Development
• 11.8 Sanofi-Aventis
  • 11.8.1 Sanofi-Aventis Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Sanofi-Aventis Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Sanofi-Aventis Antifungal Drugs Products Offered
  • 11.8.5 Sanofi-Aventis Recent Development
• 11.9 Merck
  • 11.9.1 Merck Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Merck Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Merck Antifungal Drugs Products Offered
  • 11.9.5 Merck Recent Development
• 11.10 Kramer Laboratories
  • 11.10.1 Kramer Laboratories Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Kramer Laboratories Antifungal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Kramer Laboratories Antifungal Drugs Products Offered
  • 11.10.5 Kramer Laboratories Recent Development
• 11.11 Enzon Pharmaceuticals
• 11.12 Gilead

12 Future Forecast

• 12.1 Antifungal Drugs Market Forecast by Regions
  • 12.1.1 Global Antifungal Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Antifungal Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Antifungal Drugs Market Forecast by Product
  • 12.2.1 Global Antifungal Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Antifungal Drugs Revenue Forecast by Product 2019-2025
• 12.3 Antifungal Drugs Market Forecast by End User
• 12.4 North America Antifungal Drugs Forecast
• 12.5 Europe Antifungal Drugs Forecast
• 12.6 Asia Pacific Antifungal Drugs Forecast
• 12.7 Central & South America Antifungal Drugs Forecast
• 12.8 Middle East and Africa Antifungal Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Antifungal Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

An antifungal drug, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others. Such drugs are usually obtained by a doctor's prescription, but a few are available OTC (over-the-counter).
Asia Pacific is expected to be the fastest growing regional segment for the antifungal drug market in 2017 within the forecast period due to the rapid spread of fungal infection in this region. Asia Pacific accounted as a leading market of the global antifungal drug market in 2015 in terms of growth.
The global Antifungal Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antifungal Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Antifungal Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antifungal Drugs in these regions.
This research report categorizes the global Antifungal Drugs market by top players/brands, region, type and end user. This report also studies the global Antifungal Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Asperqillus
Alternaria
Abbott Laboratories
Pfizer
GlaxoSmithKline
Bayer Healthcare
Novartis
Sanofi-Aventis
Merck
Kramer Laboratories
Enzon Pharmaceuticals
Gilead

Market size by Product
Clotrimazole.
Econazole.
Miconazole.
Terbinafine.
Fluconazole.
Ketoconazole.
Amphotericin.
Market size by End User
Hospitals
Clinics

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Antifungal Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Antifungal Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Antifungal Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Antifungal Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Antifungal Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antifungal Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.